Compare Gilead Sciences, Inc. (GILD) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Kraft Heinz Co — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.40B), while Kraft Heinz Co trades at $22.44 (market cap $26.66B). The key difference: Gilead Sciences, Inc. is far larger — about 6.8× Kraft Heinz Co's market cap, and Kraft Heinz Co pays the higher dividend (7.12%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Kraft Heinz Co for 129 Days on average.
| GILD | KHC | |
|---|---|---|
Market Cap | $182.40B | $26.66B |
Volume | 4,469,821 | 31,300,109 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $27.62 |
52-Week Low | $116.74 | $21.21 |
Typical Hold Time | 111 Days | 129 Days |
Enterprise Value | $205.46B | $42.98B |
Dividend Yield | 2.23% | 7.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Kraft Heinz (KHC) trades at $21.98, down 0.23% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have beaten estimates, but 2025 saw a net loss of $5.85 billion due to impairment charges, though operating cash flow remains strong at $4.46 billion. The company is executing a turnaround strategy, including a $700 million reinvestment and new product launches like Philadelphia cream cheese flavors, to revive brand relevance amid volume challenges.
The stock offers a discounted valuation with a P/E of 13.04 and P/B of 0.72, but high debt and negative ROE pose risks. Analyst consensus is cautious with a hold-heavy rating and $23.78 price target, implying modest upside. Key opportunities include cash flow stability and brand reinvestment, while risks involve persistent volume declines and competitive pressures in the consumer goods sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
